Stay current on changes and developments in corporate law with a wide variety of resources and tools.
By Jacob Rund
Juno Therapeutics won’t need to wait for a judge to decide whether it must give an investor access to records involving its $9 billion sale to Celgene Corp.
Attorneys for the biotechnology firm and the suing stockholder filed jointly with the Delaware Chancery Court June 13 to dismiss the books and records complaint. This action, not yet signed off on by presiding Judge Tamika Montgomery-Reeves, comes before the court could issue a decision or hold oral arguments.
The investor wanted to view the minutes from every Juno board meeting since Jan. 1, 2017, material provided by any other potential acquirers, financial summaries given to the board, and board documents related to the independence of its directors, among other items.
Young Hwan Kim filed the complaint in March to probe for any “wrongdoing or mismanagement” by Juno’s board members.
Attorneys representing Kim didn’t respond to requests for comment on their stipulation of dismissal. A Celgene spokesperson declined to comment.
The lawsuit alleged that the buyout of Juno may have been driven by the self interests of its board and of Celgene, which was the Seattle-based company’s largest stockholder. It also referenced the 2015 nomination of a Celgene executive to Juno’s board as a reason to suspect the deal could have been unfair.
Investors often use similar complaints as a stepping stone to subsequent litigation against a company’s directors. Delaware state courts have set a low bar for proving the need for obtaining corporate documents through this method.
The case is Kim v. Juno Therapeutics Inc. , Del. Ch., No. 2018-0140, stipulation filed 6/13/18 .
To contact the reporter on this story: Jacob Rund in Washington at firstname.lastname@example.org
To contact the editor responsible for this story: Fawn Johnson at email@example.com
Copyright © 2018 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)